Advertisement

Virchows Archiv

, Volume 473, Issue 5, pp 599–606 | Cite as

Dual staining for p16/Ki67 is a more specific test than cytology for triage of HPV-positive women

  • Carolina Areán-Cuns
  • Maria Mercado-Gutiérrez
  • Irene Paniello-Alastruey
  • Fermín Mallor-Giménez
  • Alicia Córdoba-Iturriagagoitia
  • Maria Lozano-Escario
  • Mercedes Santamaria-Martínez
Original Article
  • 193 Downloads

Abstract

Globally, cervical cancer (CC) screening is moving from cytology-based to HPV screening or a combination of both (co-testing). Most HPV-positive women clear the virus and do not develop relevant disease. Additional triage approaches are needed to reduce unnecessary colposcopy referrals. The p16/Ki67 dual stain cytology test (DSCT) is one of the most promising, but it has not (yet) been included as a recommendation in European guidelines. Previous studies in Spain on this issue are lacking. We studied the performance of p16/Ki67 DSCT for the triage of HPV-positive women in Navarra to detect precursor lesions (PLs) and CC compared to cytology only. We selected 1865 HPV-positive women with p16/Ki67 DSCT results and 304 women with an available biopsy result. Sensitivity, specificity and predictive values of the p16/Ki67 DSCT to detect underlying PLs and CC compared to cytology were calculated, using the biopsy as the gold standard. Cytology and p16/Ki67 DSCT showed similar sensitivity (99.0% vs. 98.0%), but cytology had significantly lower specificity (6.9 vs. 39.1%). Of the CIN2+/HPV+ women, triage using cytology only would have resulted in 40.2% true PLs and CC, while using p16/Ki67 DSCT this was 98.0% qualifying the women for colposcopy referral. Our results show that p16/Ki67 DSCT detects more than twice as many true PLs and CC than cytology only in this population. Thus, this test can be considered as an important additional tool in HPV testing-based screening strategies, to avoid unnecessary colposcopy referrals and to reduce health care costs.

Keywords

Cervical cancer Cytology Human papillomavirus (HPV) Screening Dual immunostaining 

Notes

Acknowledgments

We are grateful to Elena Almudévar, Rosa Guarch and Oscar Manzanilla for their advisory and for taking the last look at the manuscript. We also thank the technicians of the Pathology Department at “Complejo Hospitalario de Navarra” for their valuable contribution to this study.

Compliance with ethical standards

This manuscript complies with local ethics guidelines.

Conflict of interest

The authors declare that they have no conflicts of interest.

Financial disclosures

F. Mallor partially supported by MTM2016-77015-R (AEI, FEDER, UE).

I. Paniello partially supported by MTM2017-83506-C2-1-P.

The other authors made no disclosures.

Ethical responsibilities of author section

ACC and SMM designed the study and contributed substantially with the acquisition and interpretation of data. MGM collected the data. PAI and MGF did the data analysis. ACC wrote the manuscript. LEM and CIA contributed substantially with the interpretation of data for the work. All authors contributed revising the work critically for important intellectual content and final approval of the version to be published.

References

  1. 1.
    von Karsa L, Arbyn M, De Vuyst H et al (2015) European Guidelines for Quality Assurance in Cervical Cancer Screening - Second Edition Supplements.  https://doi.org/10.2875/93363 CrossRefGoogle Scholar
  2. 2.
    Bladé AT, Saladrigues M, del P, Gimferrer MC et al (2014) Guía de cribado del cáncer de cuello de útero en España, 2014. Progr Obstet Ginecol 57(1):1–53.  https://doi.org/10.1016/S0304-5013(14)73068-7 CrossRefGoogle Scholar
  3. 3.
    Carozzi FM (2007) Combined analysis of HPV DNA and p16INK4a expression to predict prognosis in ASCUS and LSIL pap smears. Coll Antropol 31(Suppl 2):103–106Google Scholar
  4. 4.
    Wentzensen N, Bergeron C, Cas F, Vinokurova S, von Knebel Doeberitz M. Triage of women with ASCUS and LSIL cytology. Cancer 2006;111(1):58–66.  https://doi.org/10.1002/cncr.22420 CrossRefGoogle Scholar
  5. 5.
    Ordi J, Sagasta A, Munmany M, Rodríguez-Carunchio L, Torné A, Del Pino M (2014) Usefulness of p16/Ki67 immunostaining in the triage of women referred to colposcopy. Cancer Cytopathol. 122(3):227–235.  https://doi.org/10.1002/cncy.21366 CrossRefGoogle Scholar
  6. 6.
    Wentzensen N, Fetterman B, Castle PE et al (2015) p16/Ki-67 dual stain cytology for detection of cervical precancer in HPV-positive women. J Natl Cancer Inst 107(12):djv257.  https://doi.org/10.1093/jnci/djv257 CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Waldstrøm M, Christensen RK, Ornskov D (2013) Evaluation of p16INK4a/Ki-67 dual stain in comparison with an mRNA human papillomavirus test on liquid-based cytology samples with low-grade squamous intraepithelial lesion. Cancer Cytopathol. 121(3):136–145.  https://doi.org/10.1002/cncy.21233 CrossRefGoogle Scholar
  8. 8.
    Wentzensen N, Schwartz L, Zuna RE, Smith K, Mathews C, Gold MA, Allen RA, Zhang R, Dunn ST, Walker JL, Schiffman M (2012) Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin Cancer Res 18(15):4154–4162.  https://doi.org/10.1158/1078-0432.CCR-12-0270 CrossRefPubMedCentralPubMedGoogle Scholar
  9. 9.
    Bergeron C, Ronco G, Reuschenbach M, Wentzensen N, Arbyn M, Stoler M, von Knebel Doeberitz M (2015) The clinical impact of using p16INK4a immunochemistry in cervical histopathology and cytology: an update of recent developments. Int J Cancer 136(12):2741–2751.  https://doi.org/10.1002/ijc.28900 CrossRefGoogle Scholar
  10. 10.
    Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA (2009) HPV screening for cervical cancer in rural India. N Engl J Med 360(14):1385–1394.  https://doi.org/10.1056/NEJMoa0808516 CrossRefGoogle Scholar
  11. 11.
    Kisser A, Zechmeister-Koss I (2015) A systematic review of p16/Ki-67 immuno-testing for triage of low grade cervical cytology. BJOG An Int J Obstet Gynaecol 122(1):64–70.  https://doi.org/10.1111/1471-0528.13076 CrossRefGoogle Scholar
  12. 12.
    Ovestad IT, Dalen I, Hansen E, Loge JLD, Dybdahl BM, Dirdal MB, Moltu P, Berland JM (2017) Clinical value of fully automated p16/Ki-67 dual staining in the triage of HPV-positive women in the Norwegian Cervical Cancer Screening Program. Cancer Cytopathol. 125(4):283–291.  https://doi.org/10.1002/cncy.21807 CrossRefGoogle Scholar
  13. 13.
    Wentzensen N, Schiffman M, Palmer T, Arbyn M (2016) Triage of HPV positive women in cervical cancer screening. J Clin Virol 76(Suppl 1):S49–S55.  https://doi.org/10.1016/j.jcv.2015.11.015 CrossRefGoogle Scholar
  14. 14.
    Ebisch RMF, Van Der Horst J, Hermsen M et al (2017) Evaluation of p16/Ki-67 dual-stained cytology as triage test for high-risk human papillomavirus-positive women. Mod Pathol 30(7):1021–1031.  https://doi.org/10.1038/modpathol.2017.16 CrossRefGoogle Scholar
  15. 15.
    Rossi P, Borghi L, Ferro R, Mencarelli R (2015) A population of 1136 HPV DNA-HR positive women: expression of p16 INK4a / Ki67 dual-stain cytology and cytological diagnosis. Histological correlations and cytological follow up. Pathologica 107(3–4):185–191Google Scholar
  16. 16.
    Luttmer R, Dijkstra MG, Snijders PJF, Berkhof J, van Kemenade FJ, Rozendaal L, Helmerhorst TJM, Verheijen RHM, ter Harmsel WA, van Baal WM, Graziosi PGCM, Quint WGV, Spruijt JWM, van Dijken DKE, Heideman DAM, Meijer CJLM (2016) p16/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population. Mod Pathol 29(8):870–878.  https://doi.org/10.1038/modpathol.2016.80 CrossRefGoogle Scholar
  17. 17.
    Benevolo M, Allia E, Gustinucci D, Rollo F, Bulletti S, Cesarini E, Passamonti B, Giovagnoli MR, Carico E, Carozzi FM, Mongia A, Fantacci G, Confortini M, Rubino T, Fodero C, Prandi S, Marchi N, Farruggio A, Coccia A, Macrì L, Ghiringhello B, Ronco G, Bragantini E, Polla E, Maccallini V, Negri G, Giorgi Rossi P, for the New Technologies for Cervical Cancer Screening 2 (NTCC2) Working Group (2017) Interobserver reproducibility of cytologic p16INK4a/Ki-67 dual immunostaining in human papillomavirus-positive women. Cancer Cytopathol. 125(3):212–220.  https://doi.org/10.1002/cncy.21800 CrossRefGoogle Scholar
  18. 18.
    You K, Guo YL, Geng L, Qiao J (2013) Correlation of cervical intraepithelial neoplasia with expressions of p16 and Ki67 in exfoliated cervical cells in fluid-based thin-layer samples. Eur J Gynaecol Oncol 34(6):535–539Google Scholar
  19. 19.
    Wentzensen N, Arbyn M, Berkhof J, Bower M, Canfell K, Einstein M, Farley C, Monsonego J, Franceschi S (2017) Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice. Int J Cancer 140(10):2192–2200.  https://doi.org/10.1002/ijc.30579 CrossRefGoogle Scholar
  20. 20.
    Blatt AJ, Kennedy R, Luff RD, Austin RM, Rabin DS (2015) Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol. 123(5):282–288.  https://doi.org/10.1002/cncy.21544 CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.
    Tracht JM, Davis AD, Fasciano DN, Eltoum IEA (2017) Discrepant HPV/cytology cotesting results: are there differences between cytology-negative versus HPV-negative cervical intraepithelial neoplasia? Cancer Cytopathol. 125(10):795–805.  https://doi.org/10.1002/cncy.21905 CrossRefGoogle Scholar
  22. 22.
    Guo M, Khanna A, Wang J, Dawlett MA, Kologinczak TL, Lyons GR, Bassett RL Jr, Sneige N, Gong Y, Bevers TB (2017) Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening. Cancer Cytopathol. 125(8):644–651.  https://doi.org/10.1002/cncy.21877 CrossRefGoogle Scholar
  23. 23.
    Ascunce N, Barcos A, Ederra M, Erdozain NRR (2008) Citologías ginecológicas en Navarra 2001–2007. Inst Salud Pública-Sección Detección Precoz:1–89Google Scholar
  24. 24.
    Tao X, Austin RM, Zhang H, Zhang L, Xiao J, Zhou X, Wang L, Zhao C (2017) Histopathologic follow-up and HPV test results with HSIL Papanicolaou test results in China’s largest academic women’s hospital. Cancer Cytopathol. 125(12):947–953.  https://doi.org/10.1002/cncy.21914 CrossRefGoogle Scholar
  25. 25.
    Yu L-L, Chen W, Lei X-Q et al (2016) Evaluation of p16/Ki-67 dual staining in detection of cervical precancer and cancers: a multicenter study in China. Oncotarget 7(16):21181–21189.  https://doi.org/10.18632/oncotarget.8307 CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    Ikenberg H, Bergeron C, Schmidt D, Griesser H, Alameda F, Angeloni C, Bogers J, Dachez R, Denton K, Hariri J, Keller T, von Knebel Doeberitz M, Neumann HH, Puig-Tintore LM, Sideri M, Rehm S, Ridder R, for the PALMS Study Group (2013) Screening for cervical cancer precursors with p16/Ki-67 dual-stained cytology: results of the PALMS study. J Natl Cancer Inst 105(20):1550–1557.  https://doi.org/10.1093/jnci/djt235 CrossRefPubMedCentralPubMedGoogle Scholar
  27. 27.
    Mercado Gutiérrez MR, Arean Cuns C, Gómez Dorronsoro ML et al (2017) Influence of age in the prevalence of high-risk human papiloma virus in women with pre-neoplasic cervical lesions in Navarra, Spain. Rev Esp Salud Publica 91:1–8 http://www.ncbi.nlm.nih.gov/pubmed/28181989 Google Scholar
  28. 28.
    Uijterwaal MH, Polman NJ, Witte BI, van Kemenade FJ, Rijkaart D, Berkhof J, Balfoort-van der Meij GAMA, Ridder R, Snijders PJF, Meijer CJLM (2015) Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data. Int J Cancer 136(10):2361–2368.  https://doi.org/10.1002/ijc.29290 CrossRefGoogle Scholar
  29. 29.
    Uijterwaal MH, Witte BI, Van Kemenade FJ et al (2014) Triaging borderline/mild dyskaryotic Pap cytology with p16/Ki-67 dual-stained cytology testing: cross-sectional and longitudinal outcome study. Br J Cancer 110(6):1579–1586.  https://doi.org/10.1038/bjc.2014.34 CrossRefPubMedCentralPubMedGoogle Scholar
  30. 30.
    Petry KU, Schmidt D, Scherbring S, Luyten A, Reinecke-Lüthge A, Bergeron C, Kommoss F, Löning T, Ordi J, Regauer S, Ridder R Gynecologic Oncology Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. Gynecol Oncol 2011;121(3):505–509.  https://doi.org/10.1016/j.ygyno.2011.02.033 CrossRefGoogle Scholar
  31. 31.
    Schmidt D, Bergeron C, Denton KJ, Ridder R (2011) p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL Papanicolaou cytology. Cancer Cytopathol 119(3):158–166.  https://doi.org/10.1002/cncy.20140 CrossRefGoogle Scholar
  32. 32.
    Killeen JL, Dye T, Grace C, Hiraoka M (2014) Improved abnormal Pap smear triage using cervical cancer biomarkers. J Low Genit Tract Dis 18(1):1–7.  https://doi.org/10.1097/LGT.0b013e31828aeb39 CrossRefGoogle Scholar
  33. 33.
    Bergeron C, Ikenberg H, Sideri M, Denton K, Bogers J, Schmidt D, Alameda F, Keller T, Rehm S, Ridder R, for the PALMS Study Group (2015) Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results. Cancer Cytopathol. 123(6):373–381.  https://doi.org/10.1002/cncy.21542 CrossRefGoogle Scholar
  34. 34.
    Loghavi S, Walts AE, Bose S (2013) CINtec® PLUS dual immunostain: a triage tool for cervical pap smears with atypical squamous cells of undetermined significance and low grade squamous intraepithelial lesion. Diagn Cytopathol 41(7):582–587.  https://doi.org/10.1002/dc.22900 CrossRefGoogle Scholar
  35. 35.
    Edgerton N, Cohen C, Siddiqui MT (2013) Evaluation of CINtec PLUS® testing as an adjunctive test in ASC-US diagnosed SurePath® preparations. Diagn Cytopathol 41(1):35–40.  https://doi.org/10.1002/dc.21757 CrossRefGoogle Scholar
  36. 36.
    White C, Bakhiet S, Bates M, Keegan H, Pilkington L, Ruttle C, Sharp L, O’ Toole S, Fitzpatrick M, Flannelly G, O’ Leary JJ, Martin CM (2016) Triage of LSIL/ASC-US with p16/Ki-67 dual staining and human papillomavirus testing: a 2-year prospective study. Cytopathology 27(4):269–276.  https://doi.org/10.1111/cyt.12317 CrossRefGoogle Scholar
  37. 37.
    Carozzi F, Gillio-Tos A, Confortini M, del Mistro A, Sani C, de Marco L, Girlando S, Rosso S, Naldoni C, Dalla Palma P, Zorzi M, Giorgi-Rossi P, Segnan N, Cuzick J, Ronco G, NTCC working group (2013) Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 14(2):168–176.  https://doi.org/10.1016/S1470-2045(12)70529-6 CrossRefGoogle Scholar
  38. 38.
    Iftner T, Becker S, Neis KJ, Castanon A, Iftner A, Holz B, Staebler A, Henes M, Rall K, Haedicke J, von Weyhern CH, Clad A, Brucker S, Sasieni P (2015) Head-to-head comparison of the RNA-based aptima human papillomavirus (HPV) assay and the DNA-based hybrid capture 2 HPV test in a routine screening population of women aged 30 to 60 years in Germany. J Clin Microbiol 53(8):2509–2516.  https://doi.org/10.1128/JCM.01013-15 CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Carolina Areán-Cuns
    • 1
  • Maria Mercado-Gutiérrez
    • 1
  • Irene Paniello-Alastruey
    • 2
  • Fermín Mallor-Giménez
    • 2
  • Alicia Córdoba-Iturriagagoitia
    • 1
  • Maria Lozano-Escario
    • 3
  • Mercedes Santamaria-Martínez
    • 1
  1. 1.Department of Pathology, Complejo Hospitalario de NavarraPamplonaSpain
  2. 2.Department of Statistics and Operative InvestigationUniversidad Pública de NavarraPamplonaSpain
  3. 3.Department of PathologyClínica Universidad de NavarraPamplonaSpain

Personalised recommendations